Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Suvodirsen in Duchenne Muscular Dystrophy
NCT03508947Phase 1Completed
- Sponsor
- Wave Life Sciences
- Start
- Jan 2018
- Primary completion
- Mar 2019
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 7
01
Overview
Phase 1, randomised, double-blind trial of Suvodirsen in Duchenne muscular dystrophy (DMD) (5 cohorts), sponsored by Wave Life Sciences. Primary endpoints: Number of patients with adverse events (AEs), Severity of AEs and 2 more. Started Jan 2018; status: completed.
02
Drugs
Suvodirsen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT03508947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03508947.